Metsera (NASDAQ:MTSR) Hits New 1-Year Low – Should You Sell?

Metsera, Inc. (NASDAQ:MTSR) reached a new 52-week low during trading on Wednesday . The company traded as low as $22.29 and last traded at $22.43, with a volume of 150051 shares traded. The stock had previously closed at $24.51.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MTSR shares. Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Guggenheim assumed coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price for the company. Cantor Fitzgerald started coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Finally, Bank of America began coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price objective for the company.

Metsera Stock Down 4.5 %

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.